Effective treatment and sobaiovir and daclatasvir in treatment of Hepatitis C

Efficacy and safety of Sobiovir(Sofosbuvir) and Daklibiox (Daclatasvir) for treatment of Hepatitis C in patient with thalassemia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017052426097N2

Enrollment

100

Registered

2017-06-24

Start date

2016-12-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic viral hepatitis C. Chronic viral hepatitis C

Interventions

Antiretroviral therapy in all patients with Daclatacvirr and sobaiovir - before and after treatment.

Treatment - Drugs

Antiretroviral therapy in all patients with Daclatacvirr and sobaiovir - before and after treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Persons with thalassemia major, which has a history of hepatitis C are and once in the past but failed treatment with interferon treatment were enrolled if they consent

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
The number of hepatitis C virus. Timepoint: 18/5000 After treatment. Method of measurement: The number of virus by PCR.	—

Secondary

Measure	Time frame
Complications of Treatment. Timepoint: Questionnaires and blood tests. Method of measurement: Blood samples and questionnaires of Complications , per month.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactvafaeimanesh jamshid

Iran university of medical silences

jvafaeemanesh@yahoo.comj.vafaeemanesh@muq.ac.ir+98 21 8894 0489

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026